免疫调节分子在肿瘤化疗敏感性调控中的研究进展  

Progression of immunomodulatory molecules in the change of cancer chemotherapy sensitivity

作　　者：吕丽[1,2] 宋鑫[1,2] 

机构地区：[1]昆明医科大学第三附属医院 [2]云南省肿瘤医院生物治疗中心,昆明市650118

出　　处：《中国肿瘤临床》2014年第24期1597-1601,共5页Chinese Journal of Clinical Oncology

基　　金：国家高技术研究发展计划(863计划)资助项目(编号:2012AA02A201);国家自然科学基金项目(编号:81060185、81260307、81470005);国家卫计委肿瘤科国家临床重点专科项目(2013-2014);云南省高层次卫生技术人才-领军人才项目(编号:L-201213);云南省应用基础研究面上项目(编号:2012FB069);云南省教育厅科学研究基金项目(编号:2013J048)资助~~

摘　　要：原发性或获得性耐药是肿瘤化疗失败的主要原因,如何逆转化疗耐药是当前肿瘤化疗研究热点。新近研究发现,免疫调节分子参与肿瘤化疗耐药,靶向干预免疫调节分子可以逆转化疗耐药,引起国内外学者的极度关注。研究已证实,免疫调节分子PD-L1、B7-H3、HMGB1、TRAIL、My D88、细胞因子(TNF-α、IFN-α、IL-6)等在调控机体免疫功能的同时,也能调控肿瘤细胞耐药特性,为逆转肿瘤化疗耐药提供了新思路。本文就免疫调节分子在肿瘤化疗敏感性改变中的研究进展作一综述,旨在为生物化疗新方案的实施提供理论依据。Intrinsic or acquired chemo-resistance is the main reason for chemotherapy failure, and thus finding ways to reverse chemo-resistance has become an interesting topic for research. Studies have revealed that immunomodulatory molecules are involved in cancer chemo-resistance. Hence, interventions that target immunomodulatory molecules to reverse chemo-resistance have attracted a great deal of concern from domestic and foreign scholars. Immunomodulatory molecules, such as PD-L1, B7-H3, HMGB1, TRAIL, MyD88, and Cytokines （TNF-α, IFN-α, IL-6）, have been proven to take part in regulating immune function and tumor drug-resistance characteristics, thereby providing new ideas to the reversal of tumor chemo-resistance. This artide reviews the progression of immuno-modulatory molecules with the change in cancer chemotherapy sensitivity to provide a theoretical basis for the application of new thera-peutic regimen of bio-chemotherapy.

关 键 词：免疫调节分子 细胞因子 肿瘤 化疗耐药 

分 类 号：R730.53[医药卫生—肿瘤]